Compare AYI & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AYI | TGTX |
|---|---|---|
| Founded | 2001 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 8.5B |
| IPO Year | 2001 | 2008 |
| Metric | AYI | TGTX |
|---|---|---|
| Price | $306.06 | $56.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $369.17 | $49.80 |
| AVG Volume (30 Days) | 206.2K | ★ 1.5M |
| Earning Date | 04-02-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | ★ 11.45 | 0.17 |
| Revenue | ★ $3,461,000,000.00 | $2,785,000.00 |
| Revenue This Year | $7.51 | $49.08 |
| Revenue Next Year | $5.14 | $26.69 |
| P/E Ratio | ★ $27.14 | $341.82 |
| Revenue Growth | ★ 4.05 | N/A |
| 52 Week Low | $257.04 | $26.76 |
| 52 Week High | $380.17 | $59.30 |
| Indicator | AYI | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 61.78 |
| Support Level | N/A | $51.76 |
| Resistance Level | N/A | $58.12 |
| Average True Range (ATR) | 0.00 | 2.02 |
| MACD | 0.00 | 0.21 |
| Stochastic Oscillator | 0.00 | 84.03 |
Acuity is a leading industrial technology company that offers lighting, lighting controls, and intelligent building solutions. It designs, manufactures, and brings to market products and services relating to these and other offerings. Acuity has two reportable segments: Acuity Brands Lighting and Acuity Intelligent Spaces. ABL sells commercial, architectural, and specialty lighting, including components and control systems. AIS offers building management and audio/visual solutions to help make buildings intelligent.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.